ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD

Zhejiang Jiuzhou Pharmaceutical Co., Ltd

603456

CNE100001W36

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
15.12 ^CNY	-1.56%		-4.73%	-37.55%

Apr. 08	Zhejiang Jiuzhou Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 08	Jiuzhou Pharmaceutical Gets Nod to Market Sitagliptin Metformin Tablets; Shares Drop 4%	MT

Zhejiang Jiuzhou Pharmaceutical Co., Ltd(XSSC:603456) added to S&P Global BMI Index

September 20, 2021 at 12:00 am EDT

Latest news about Zhejiang Jiuzhou Pharmaceutical Co., Ltd

Zhejiang Jiuzhou Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 08	CI
Jiuzhou Pharmaceutical Gets Nod to Market Sitagliptin Metformin Tablets; Shares Drop 4%	Apr. 08	MT
Ruibo Pharmaceutical Co., Ltd. announced that it expects to receive CNY 300 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd	Apr. 07	CI
Ruibo Pharmaceutical Technology Co., Ltd. announced that it expects to receive CNY 15 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd	Apr. 07	CI
Tranche Update on Zhejiang Jiuzhou Pharmaceutical Co., Ltd's Equity Buyback Plan announced on January 5, 2024.	Apr. 01	CI
Jiuzhou Pharma to Build $42 Million CRO Platform in Japan	Jan. 23	MT
Zhejiang Jiuzhou Pharmaceutical Co., Ltd announces an Equity Buyback for CNY 100 million worth of its shares.	Jan. 04	CI
Zhejiang Jiuzhou Pharmaceutical Co., Ltd authorizes a Buyback Plan.	Jan. 03	CI
Ruibo Pharmaceutical Technology Co., Ltd. announced that it has received CNY 50 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd	Dec. 26	CI
Zhejiang Siwei Pharmaceutical Technology Co., Ltd announced that it has received CNY 100 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd	Dec. 26	CI
Ruibo Pharmaceutical Technology Co., Ltd. announced that it expects to receive CNY 50 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd	Nov. 14	CI
Zhejiang Siwei Pharmaceutical Technology Co., Ltd announced that it expects to receive CNY 100 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd	Nov. 14	CI
Zhejiang Jiuzhou Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Ruibo Pharmaceutical Technology Co., Ltd. announced that it has received CNY 20 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd	23-09-25	CI
Ruibo Pharmaceutical Technology Co., Ltd. announced that it expects to receive CNY 20 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd	23-09-03	CI
Jiuzhou Pharmaceutical Logs Double-Digit Growth in H1 Earnings on Expanded CDMO Operations	23-08-15	MT
Zhejiang Jiuzhou Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-09	CI
Jiuzhou Pharma to Set Up Singapore Subsidiary	23-08-08	MT
Ruihua Pharmaceutical Co., Ltd. announced that it has received CNY 185 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd	23-06-15	CI
Jiuzhou Pharma Gets Drug Registration Certificate for Carbamazepine Sustained-release Tablets	23-06-13	MT
Zhejiang Jiuzhou Pharmaceutical Co., Ltd(SHSE:603456) dropped from Shanghai Stock Exchange 180 Value Index	23-06-09	CI
Zhejiang Jiuzhou Pharmaceutical Co., Ltd(SHSE:603456) dropped from SSE 180 Index	23-06-09	CI
Zhejiang Jiuzhou Pharmaceutical Co., Ltd's Equity Buyback announced on September 1, 2022 has closed with 2,871,000 shares, representing 0.33% for CNY 99.99 million.	23-05-31	CI
Tranche Update on Zhejiang Jiuzhou Pharmaceutical Co., Ltd's Equity Buyback Plan announced on September 1, 2022.	23-05-31	CI
Zhejiang Jiuzhou Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI

Chart Zhejiang Jiuzhou Pharmaceutical Co., Ltd

Duration

Period

Chart Zhejiang Jiuzhou Pharmaceutical Co., Ltd

More charts

Zhejiang Jiuzhou Pharmaceutical Co.,Ltd. is a China-based company principally engaged in the research, development, production and sales of chemical Active Pharmaceutical Ingredients (API) and intermediates. The Company mainly operates through two segments, including the New Drug and Intermediates Contract Development and Manufacturing Organization (CDMO) segment and the Specialty APIs and Intermediates segment. The New Drug and Intermediates CDMO segment mainly provides services for innovative medicines of pre-clinical chemical manufacturing and controls (CMC), clinical phases I, II and III, new drug application (NDA) and various stages after going public. The Specialty API and Intermediates segments mainly provides services including patent breakthroughs, production process improvement, drug certificate declaration, and cGMP standard commercial production for patented expired or soon-to-be-expired drugs for global chemical and generic drug manufacturers.

Sector

Pharmaceuticals

Calendar

2024-04-24 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Zhejiang Jiuzhou Pharmaceutical Co., Ltd

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.12 CNY

Average target price

23.31 CNY

Spread / Average Target

+54.17%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD	-37.55%	1.88B
ELI LILLY AND COMPANY	+27.97%	672B
NOVO NORDISK A/S	+23.71%	550B
JOHNSON & JOHNSON	-7.02%	351B
MERCK & CO., INC.	+14.85%	317B
ABBVIE INC.	+6.25%	292B
ASTRAZENECA PLC	+2.13%	211B
NOVARTIS AG	-0.38%	203B
ROCHE HOLDING AG	-10.10%	194B
PFIZER, INC.	-11.81%	144B

Other Pharmaceuticals